(TAK) Takeda Pharmaceutical - Ratings and Ratios
Gastroenterology,Rare,Disease,Plasma,Oncology
TAK EPS (Earnings per Share)
TAK Revenue
Description: TAK Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited is a global pharmaceutical company that engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. The companys diverse portfolio spans multiple therapeutic areas, including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience, with a range of brands such as Entyvio, Ninlaro, and Vyvanse.
To evaluate Takedas performance, key performance indicators (KPIs) such as revenue growth, R&D expenditure as a percentage of sales, and pipeline development can be considered. With a history dating back to 1781, Takeda has established itself as a significant player in the pharmaceutical industry. Its collaborations and licensing agreements with various companies, including BioMarin, Neurocrine Biosciences, and Seagen, demonstrate its commitment to innovation and expansion.
From a financial perspective, Takedas market capitalization stands at approximately $48 billion, with a forward P/E ratio of 14.53, indicating a relatively attractive valuation compared to its peers. The companys return on equity (RoE) is 1.48%, which may be considered low, but this could be due to various factors such as significant R&D investments or one-time expenses. To gain a deeper understanding, analyzing the companys cash flow statements, debt-to-equity ratio, and operating margins would be essential.
Takedas product portfolio and pipeline are critical to its success. The companys focus on rare diseases, oncology, and neuroscience positions it well for potential growth areas. Evaluating the commercial potential of its key products, such as Entyvio and Ninlaro, and assessing the competitive landscape in these therapeutic areas, would provide valuable insights into the companys prospects.
TAK Stock Overview
| Market Cap in USD | 48,697m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2008-10-27 |
TAK Stock Ratings
| Growth Rating | 39.9% |
| Fundamental | 56.9% |
| Dividend Rating | 35.2% |
| Return 12m vs S&P 500 | -9.67% |
| Analyst Rating | 4.50 of 5 |
TAK Dividends
| Dividend Yield 12m | 4.59% |
| Yield on Cost 5y | 4.52% |
| Annual Growth 5y | -1.96% |
| Payout Consistency | 91.9% |
| Payout Ratio | 0.4% |
TAK Growth Ratios
| Growth Correlation 3m | 15.9% |
| Growth Correlation 12m | 69.4% |
| Growth Correlation 5y | 3% |
| CAGR 5y | 8.60% |
| CAGR/Max DD 3y | 0.37 |
| CAGR/Mean DD 3y | 0.88 |
| Sharpe Ratio 12m | 1.66 |
| Alpha | -9.67 |
| Beta | 0.682 |
| Volatility | 17.44% |
| Current Volume | 2820.5k |
| Average Volume 20d | 2820.5k |
| Stop Loss | 14.6 (-3.3%) |
| Signal | -0.73 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (136.88b TTM) > 0 and > 6% of Revenue (6% = 268.81b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.67% (prev 14.55%; Δ -6.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 1102.30b > Net Income 136.88b (YES >=105%, WARN >=100%) |
| Net Debt (4155.93b) to EBITDA (1193.98b) ratio: 3.48 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.18b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 61.60% (prev 58.26%; Δ 3.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 29.64% (prev 27.20%; Δ 2.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.93 (EBITDA TTM 1193.98b / Interest Expense TTM 229.64b) >= 6 (WARN >= 3) |
Altman Z'' 1.05
| (A) 0.02 = (Total Current Assets 2513.12b - Total Current Liabilities 2169.59b) / Total Assets 14004.54b |
| (B) 0.08 = Retained Earnings (Balance) 1156.69b / Total Assets 14004.54b |
| (C) 0.03 = EBIT TTM 443.17b / Avg Total Assets 15116.11b |
| (D) 0.40 = Book Value of Equity 2851.40b / Total Liabilities 7138.36b |
| Total Rating: 1.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.94
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.60% = 3.80 |
| 3. FCF Margin 19.24% = 4.81 |
| 4. Debt/Equity 0.66 = 2.29 |
| 5. Debt/Ebitda 3.77 = -2.46 |
| 6. ROIC - WACC -3.48% = -4.35 |
| 7. RoE 1.95% = 0.16 |
| 8. Rev. Trend 55.18% = 2.76 |
| 9. Rev. CAGR 3.67% = 0.46 |
| 10. EPS Trend -21.42% = -0.54 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of TAK shares?
Over the past week, the price has changed by -1.11%, over one month by +2.03%, over three months by +0.20% and over the past year by +6.82%.
Is Takeda Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TAK is around 14.64 USD . This means that TAK is currently overvalued and has a potential downside of -3.05%.
Is TAK a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TAK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.3 | 21.3% |
| Analysts Target Price | 18.3 | 21.3% |
| ValueRay Target Price | 15.9 | 5.5% |
Last update: 2025-09-12 04:45
TAK Fundamental Data Overview
CCE Cash And Equivalents = 350.01b JPY (last quarter)
P/E Trailing = 52.7241
P/E Forward = 15.0376
P/S = 0.0109
P/B = 1.0365
P/EG = 0.4412
Beta = 0.271
Revenue TTM = 4480.25b JPY
EBIT TTM = 443.17b JPY
EBITDA TTM = 1193.98b JPY
Long Term Debt = 4134.80b JPY (from longTermDebt, last quarter)
Short Term Debt = 371.14b JPY (from shortTermDebt, last quarter)
Debt = 4505.94b JPY (Calculated: Short Term 371.14b + Long Term 4134.80b)
Net Debt = 4155.93b JPY (from netDebt column, last quarter)
Enterprise Value = 11334.91b JPY (7178.97b + Debt 4505.94b - CCE 350.01b)
Interest Coverage Ratio = 1.93 (Ebit TTM 443.17b / Interest Expense TTM 229.64b)
FCF Yield = 7.60% (FCF TTM 861.91b / Enterprise Value 11334.91b)
FCF Margin = 19.24% (FCF TTM 861.91b / Revenue TTM 4480.25b)
Net Margin = 3.06% (Net Income TTM 136.88b / Revenue TTM 4480.25b)
Gross Margin = 61.60% ((Revenue TTM 4480.25b - Cost of Revenue TTM 1720.37b) / Revenue TTM)
Tobins Q-Ratio = 3.98 (Enterprise Value 11334.91b / Book Value Of Equity 2851.40b)
Interest Expense / Debt = 2.38% (Interest Expense 107.16b / Debt 4505.94b)
Taxrate = 38.23% (66.94b / 175.08b)
NOPAT = 273.73b (EBIT 443.17b * (1 - 38.23%))
Current Ratio = 1.16 (Total Current Assets 2513.12b / Total Current Liabilities 2169.59b)
Debt / Equity = 0.66 (Debt 4505.94b / last Quarter total Stockholder Equity 6865.26b)
Debt / EBITDA = 3.77 (Net Debt 4155.93b / EBITDA 1193.98b)
Debt / FCF = 5.23 (Debt 4505.94b / FCF TTM 861.91b)
Total Stockholder Equity = 7034.84b (last 4 quarters mean)
RoA = 0.98% (Net Income 136.88b, Total Assets 14004.54b )
RoE = 1.95% (Net Income TTM 136.88b / Total Stockholder Equity 7034.84b)
RoCE = 3.97% (Ebit 443.17b / (Equity 7034.84b + L.T.Debt 4134.80b))
RoIC = 2.33% (NOPAT 273.73b / Invested Capital 11762.98b)
WACC = 5.81% (E(7178.97b)/V(11684.92b) * Re(8.53%)) + (D(4505.94b)/V(11684.92b) * Rd(2.38%) * (1-Tc(0.38)))
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 73.16% ; FCFE base≈688.31b ; Y1≈566.65b ; Y5≈407.42b
Fair Price DCF = 2181 (DCF Value 6888.37b / Shares Outstanding 3.16b; 5y FCF grow -21.28% → 3.0% )
Revenue Correlation: 55.18 | Revenue CAGR: 3.67%
Rev Growth-of-Growth: -5.49
EPS Correlation: -21.42 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 53.45
Additional Sources for TAK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle